Showing 1001-1010 of 2080 results for "".
Kamedis Botanically-based Regimen for Dandruff
https://practicaldermatology.com/topics/general-topics/kamedis-botanically-based-regimen-for-dandruff/18579/Kamedis brings innovation to the treatment of seborrheic dermatitis (SD, also called dandruff) with a botanically-based 2-step hair care system. The two-step Kamedis system for seborrheic dermatitis consists of SEBOMedis Anti-Dandruff Shampoo and Scalp Lotion. Botanical ingredients include indigo (IGalderma's Future, Allergan's Bonti Buy, and Sebacia Clearance
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-s-future-allergan-s-bonti-buy-and-sebacia-clearance--xgheloga/18233/Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million dDr. Kauvar Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-kauvar-discusses-experience-with-gemini-laser/19469/“Treating with the Gemini is very well accepted by patients because both components of the Gemini, the 1064 and the 532nm, are non-invasive lasers. So there's really no real downtime and no recuperation, and the results are predictable in our hands, and patients are very satisfied with their treatDermwireTV — Revance’s Neurotoxin Promising, Celebs Fight Melanoma with L’Oreal
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-revance-rsquo-s-neurotoxin-promising-celebs-fight-melanoma-with-l-rsquo-oreal/19138/In this weeks DermwireTV, patient safety is explored, L'Oreal supports melanoma research and Revance reports positive data for novel neurotoxin.DermwireTV — Nestle acquires Galderma; Dermatologic procedures surge
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-nestle-acquires-galderma-dermatologic-procedures-surge/19157/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine: Nestle acquires Galderma, dermatologic procedures surge, and we look ahead to the annual meeting in Denver. #DermWireDermwireTV — A big name is getting bigger; ICD-10 looms
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-a-big-name-is-getting-bigger-icd-10-looms/19163/In this premiere edition of DermWireTV, from the publishers of Practical Dermatology® magazine, we take a look at the latest acquisition by Valeant Pharmaceuticals, Inc., explore new data for Galderma's Mirvaso for rosacea, and get insights on the ICD-10 code set transition. #DermWireDermwireTV — Sun Rises, ICD-10 is Delayed…Again
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-sun-rises-icd-10-is-delayed-again/19139/In this week's DermwireTV, Sun acquires Ranbaxy, ICD-10 gets unexpectedly delayed, and Murad Alam recaps the ASLMS conference.Roflumilast Cream, 0.15%, for Atopic Dermatitis
https://practicaldermatology.com/issues/december-2024/Roflumilast-Cream-Atopic-Dermatitis/32840/Atopic dermatitis (AD) is a chronic, persistent inflammatory condition that significantly disrupts the quality of life of patients diagnosed with it. Moreover, AD presents challenges for clinicians when counseling patients on the management of their condition. Application frequency, treatment formulDermwireTV — Valeant Ups Allergan Bid, Nestle Buys Injectables, and Allergan Makes Its Case
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-valeant-ups-allergan-bid-nestle-buys-injectables-and-allergan-makes-its-case/19128/BREAKING NEWS: Valeant has increased its offer for Allergan to $72 per share. Read more. Valeant sells the rights to its aesthetic injectables to Nestle, while Allergan touts physician support and challenges Valeant's business model. In this week's edition of DermWireTV, learn about Valeant's lates- Dr. Jacob Chacko Joins Bonti's Board of Directorshttps://practicaldermatology.com/news/dr-jacob-chacko-joins-bontis-board-of-directors/2457893/Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications